Miaoqing
Jia
Health economist studying insurance coverage, medication access, and the policies that decide who gets care.
I graduated with a PhD in Economics from Boston University in 2022, and I am currently a Postdoctoral Associate at Weill Cornell Medicine. My research fields are health economics, applied microeconomics, industrial organization, and health policy.
-
/01
D-SNPs and dual eligibles with serious mental illnessNIMH R01 · claims-based analysis comparing FIDE, HIDE, and coordination-only D-SNPs
-
/02
GLP-1 access across the commercial-to-Medicare transitionEvent study on coverage transitions, formularies, and continuity of therapy
-
/03
FDA-cleared AI medical devices: adoption and accessDiffusion patterns, insurance coverage, and reimbursement
-
/04
Antibiotic resistance, drug prices, and entryTheoretical IO modeling of market structure, pricing, and resistance
- 2026 A Machine Learning Approach to Place-Based Cardiovascular Prevention in NYC published in American Journal of Preventive Medicine.
- 2026 New work in progress on GLP-1 access and antibiotic-resistance modeling.
- 2026 Fluoroquinolone Prescribing to Older Adults published in Antimicrobial Stewardship & Healthcare Epidemiology.
- 2026 Antibiotic Resistance, Drug Prices, and Entry accepted at Economics & Human Biology.
- APR 2025 Joined Weill Cornell Medicine as a Postdoctoral Associate.
A health economist working at the intersection of policy, data, and care.
Trained in applied microeconomics, industrial organization, and causal inference.
I joined the Department of Population Health Sciences at Weill Cornell Medical College in April 2025 after completing my PhD in Economics at Boston University. My research examines how insurance coverage policies — particularly Medicare Advantage, dual eligible special needs plans (D-SNPs), and Part D — affect medication access and health outcomes for populations with complex needs.
Most of my current work uses linked Medicare–Medicaid claims data and the Inovalon dataset to study D-SNP integration models, prescribing responses to regulatory signals, and treatment access for behavioral health populations. I'm supported by an NIMH R01 (MPI: McGinty and Zhang), where I lead the claims-based quantitative analysis on D-SNP enrollment and outcomes among dual eligibles with serious mental illness.
I'm preparing a K99/R00 application centered on Chronic Condition Special Needs Plans (C-SNPs) and access to care for beneficiaries with complex chronic conditions. My doctoral work, in a different vein, developed theoretical models of pharmaceutical market structures and antibiotic resistance.
Four areas I keep returning to.
My work connects insurance coverage design, pharmaceutical policy, and the health of populations whose care is fragmented across systems.
Medicare program design and dual eligibility
How does the structure of Medicare Advantage and integrated D-SNP enrollment shape healthcare quality and utilization for dual eligible beneficiaries with complex behavioral health needs? Using 20% Medicare claims samples, I evaluate FIDE, HIDE, coordination-only D-SNPs, look-alike plans, non-SNP MA, and traditional fee-for-service.
Machine learning for population health
Applying growth mixture modeling, XGBoost, and unsupervised clustering to large claims, EHR, and geographic datasets — characterizing patient trajectories, predicting acute care use from social needs screening, and identifying neighborhood archetypes for targeted intervention.
Pharmaceutical policy and prescriber response
Using comparative interrupted time series and Medicare Part D Prescriber files, I examine how regulatory signals — FDA black box warnings, scope-of-practice expansions — actually change prescribing behavior for older adults. Recent work covers fluoroquinolones and the rapid rise of GLP-1 prescribing.
Economics of pharmaceutical markets
My doctoral work developed theoretical models of how pharmaceutical market structures affect antibiotic resistance and drug innovation — examining pricing, patents, and usage restrictions as policy levers to balance resistance mitigation with innovation incentives.
Papers and working drafts.
Published, under review, and in progress.
Published & Forthcoming / 04
Fluoroquinolone Prescribing to Older Adults Following FDA Black Box Warnings: A Comparative Analysis
Antibiotic Resistance, Drug Prices, and Entry
Abstract
Antibiotics lose power to kill microbes through excessive use, commonly known as antibiotic resistance, which is modeled by future cost increase from current use. The first best incorporates the future cost externality due to current consumption. Resistance and consumer welfare deviate from first best in various market structures. Low prices under competition lead to high consumption and resistance. Competitive managed-care plans use rationing contracts, which partially internalize the resistance cost externality by restricting use. A drug monopolist fully internalizes the externality but sets a high price. We derive necessary and sufficient conditions for higher consumer surplus under monopoly than competition.
Facing a potential entrant, an incumbent may consider entry deterrence and accommodation. To deter entry, the incumbent reduces current sales to lower future cost, which alleviates antibiotic resistance. Entry accommodation gives rise to two countervailing effects: sharing the market weakens the incumbent's incentive to internalize the cost effect, raising production and resistance; but a lower future cost raises profit, leading the incumbent to reduce production and mitigate resistance.
PresentedAmerican Society of Health Economists (ASHEcon) 2025 · International Health Economics Association (iHEA) 2025 · American Economic Association / Allied Social Science Associations (AEA/ASSA) 2025 · Chinese Economists Society (CES) 2025 North American Annual Conference
Under Review / 04
Association between Enrollment in Integrated Special Needs Plans and Acute Care Utilization among Dual Eligibles with Serious Mental Illnesses
Abstract
Importance. Enrollment in integrated dual eligible special needs plans (D-SNPs) — including highly integrated D-SNPs (HIDE-SNPs) and fully integrated D-SNPs (FIDE-SNPs) — has increased among dual eligibles with serious mental illness (SMI), yet how it relates to acute care use remains unknown.
Objective. To examine the association between integrated D-SNP enrollment and acute care utilization among dual eligibles with SMI in 2022.
Design, Setting, and Participants. Retrospective cohort study of a 20% sample of dual eligibles with SMI using Medicare claims, including traditional Medicare fee-for-service (FFS) claims and Medicare Advantage (MA) encounter data.
Main Outcomes and Measures. Overall, psychiatric, and preventable hospitalization and emergency department (ED) visits, comparing enrollees in integrated D-SNPs with those in traditional Medicare, standard MA, and coordination-only (CO) D-SNPs.
Results. Among 349,163 dual eligibles with SMI (mean age 62 years; 63.1% female), after covariate adjustment HIDE-SNP enrollment was associated with a lower likelihood of overall hospitalization than Medicare FFS (−6.8 percentage points [pp]), standard MA (−1.9 pp), and CO D-SNPs (−2.4 pp), and lower psychiatric hospitalization across the same comparisons. FIDE-SNP enrollment was also associated with lower overall and psychiatric hospitalization versus CO D-SNPs. Both HIDE- and FIDE-SNPs were associated with lower preventable hospitalization than CO D-SNPs and lower 30-day readmission than Medicare FFS; differences in ED outcomes were smaller and less consistent.
Conclusions and Relevance. Enrollment in integrated D-SNPs, particularly HIDE-SNPs, was associated with lower overall, psychiatric, and preventable hospitalization among dual eligibles with SMI. Future research should assess causal relationships between integrated D-SNPs and acute care use in this population.
PresentingAmerican Society of Health Economists (ASHEcon) 2026
Prescription Denials For GLP-1 Receptor Agonists Across Commercial, Medicare, and Medicaid Coverage, 2018–2024
Abstract
GLP-1 receptor agonists (GLP-1 RAs) are transforming obesity and type 2 diabetes management, but access remains strongly shaped by payer coverage and utilization management tools, such as prior authorization, that may result in prescription denials. National, patient-level evidence on GLP-1 RA denial across payer types is needed to understand the evolving landscape of patient access.
Using a multi-payer claims database, we examined GLP-1 RA prescription denial among 3,221,310 individuals with a GLP-1 RA prescription claim from 2018 to 2024. Overall, 12.5% experienced at least one denied claim, with rates rising from 11.3% in 2018 to a peak of 16.9% in 2020 before declining to 9.3% in 2024. Denial was higher among Medicaid beneficiaries and new initiators across all years. New initiators, Medicaid coverage, obesity-only indication, tirzepatide prescription, and Black race were associated with higher odds of denial.
Results suggest that utilization management tools are shaping patients' access to GLP-1 RAs.
Changes in GLP-1 Receptor Agonist Use at the Commercial-to-Medicare Transition
Social Needs Screening and Subsequent Acute Care Utilization in a Large Safety Net Health System
Abstract
Background. Health systems increasingly screen for patients' social needs, but evidence is limited on which specific needs are most associated with subsequent acute care use.
Objective. To examine associations between patient-reported social needs and subsequent acute care utilization in a large safety-net population.
Design. Retrospective cohort study linking 2023 social needs screening data from a large safety-net health system to longitudinal electronic health records from a multi-health system clinical research network.
Participants. 20,337 adults with a primary care visit who completed social needs screening in 2023.
Main Measures. Positive screening for nine social needs domains (e.g., food insecurity, transportation-related delayed care). Outcomes were any hospitalization, any ED visit, preventable hospitalization, and preventable ED visit, using multivariable logistic regression adjusting for demographics, comorbidities, and neighborhood social conditions.
Key Results. Overall, 15.9% screened positive for ≥1 social need; the most prevalent were food insecurity (5.9%) and problems with residence (5.6%). After adjustment, positive screening for transportation-related delayed care was associated with a 6.8-percentage-point increase in the probability of ≥1 hospitalization, an 8.4-point increase in ≥1 ED visit, a 1.2-point increase in ≥1 preventable hospitalization, and a 4.2-point increase in ≥1 preventable ED visit. Housing-related problems were associated with a 4.1-point increase in ≥1 ED visit.
Conclusions. In a safety-net setting, transportation barriers showed the strongest and most consistent associations with subsequent acute care use, suggesting targeted transportation support and care-navigation strategies may be critical components of social care interventions.
Working Papers / 04
Characterizing Patient Trajectories after Hospice Live Discharge among Medicare Beneficiaries
Abstract
Background. Nearly one in five hospice enrollees is discharged alive ("live discharge"), a share that has grown in recent years, yet post-discharge prognosis is highly variable and poorly characterized.
Methods. Using a 20% random sample of 2014–2019 Medicare fee-for-service beneficiaries, we applied growth mixture modeling to biweekly Medicare spending over the 12 months following hospice live discharge, and multinomial logistic regression to identify characteristics associated with each trajectory.
Results. We identified five distinct post-discharge spending trajectories, ranging from rapid near-term mortality to prolonged survival with persistently high spending. Reason for live discharge, hospice care setting, and clinical complexity were the strongest predictors of trajectory membership.
Conclusions. Substantial heterogeneity in post-discharge trajectories points to opportunities for more personalized care planning after hospice live discharge.
Addressing the Externalities of Medicine Overconsumption
Abstract
I investigate the impact of inappropriate medicine usage on future healthcare costs in a multi-period model. The negative externality — any current medicine consumption raises future costs for the entire population — leads to market failures. The model includes forward-looking and myopic patients: the former recognize the long-term externalities of consumption, while the latter focus solely on immediate benefits. Their interaction exacerbates inefficiency, as forward-looking patients may cut consumption to limit future cost increases while myopic patients over-consume.
In a perfectly competitive market, marginal-cost pricing is inefficient because of myopic over-consumption. Under a monopolistic structure, pricing above marginal cost can curb overuse and improve social welfare by controlling future cost jumps. I further show that policy interventions such as taxes or subsidies can correct the market inefficiencies and improve healthcare outcomes.
The Effectiveness of the Health System Reform on Affecting Self-Medication in China
Abstract
Starting in 2010, the Chinese government implemented a series of national health care reforms to ensure accessible and affordable care, choosing several pilot areas with staggered implementation. Using ongoing national survey data from the China Health and Retirement Longitudinal Study (CHARLS), I analyze the impact of reform on patients' self-treatment behavior and on the severity of antibiotic abuse in China.
Through a combination of propensity score matching and difference-in-differences methods, I find that although the reform effectively reduces average monthly medical expenditures for people living within pilot areas, it is ineffective in limiting people's self-medication with antibiotics. Surprisingly, people living in pilot areas are more likely to use antibiotics after the reform.
Informal Gift Exchange in the Public Health Sector
Abstract
I study informal gift exchange in the public health sector in China. In the public system, a physician receives a fixed salary and additional payments from patients; a guilt effect from violating professional norms limits the size of informal payments. In the private system, the guilt effect vanishes because informal payment is legalized. Without the fixed salary, the physician in the private system abandons patients who offer low payments.
The distribution of patients' wealth levels and the physician's outside option determine relative welfare across the two systems. If too many patients are left behind, the regulator will support the public system.
In the classroom.
From PhD seminars to master's labs — health economics and machine learning for health policy.
Weill Cornell Medicine · Postdoctoral / 02
Machine Learning Applications in Health Policy and Research
Applications in Econometrics and Data Analysis
Guest Lectures / 02
Applied Machine Learning in Health Economics
Applying Behavioral Economics to Public Health Policy
Boston University · Doctoral / 05
QM717 · Data Analysis for Managerial Decision-Making
EC581 · Health Economics
EC571 · Energy and Environmental Economics
EC387 · Introduction to Health Economics
EC102 · Introduction to Macroeconomics
What's on my desk right now.
Active grants, ongoing analyses, and what's coming next.
Integrated D-SNPs and healthcare quality for dual eligibles with SMI
Leading the claims-based quantitative analysis comparing FIDE, HIDE, coordination-only D-SNPs, look-alike plans, non-SNP MA, and traditional fee-for-service. The first outcome evaluation of HIDE and FIDE SNPs since they emerged in 2021.
GLP-1 access across the commercial-to-Medicare transition
An event study examining how GLP-1 medication use, out-of-pocket spending, and continuity of therapy change when individuals age into Medicare from commercial insurance — a coverage transition with sharply different formularies, prior authorization, and cost-sharing structures.
Adoption and access for FDA-cleared AI medical devices
Examining diffusion patterns of FDA-cleared AI/ML-enabled medical devices and what insurance and reimbursement structures mean for patient access — including how Medicare and commercial coverage decisions shape uptake across specialties.
K99/R00 — Chronic Condition Special Needs Plans (C-SNPs) and access to care
Building toward an independent research program centered on Chronic Condition Special Needs Plans (C-SNPs) — how this less-studied corner of the Medicare landscape shapes enrollment, utilization, and access to care for beneficiaries with complex chronic conditions.
Antibiotic resistance, drug prices, and entry — theoretical modeling
Industrial-organization theory of how drug prices, market structure, and entry shape antibiotic consumption and resistance — extending the framework behind my forthcoming Economics & Human Biology paper toward dynamic competition and the policy levers that balance resistance mitigation with innovation incentives.
Methods I keep coming back to
Difference-in-differences with staggered adoption, instrumental variables for plan choice, and how to draw causal inferences from claims data when enrollment in any given plan is anything but random.
A life outside the claims data.
Cats, travel, and the parts of myself that don't fit on a CV.
Lemon
My most loyal research assistant — a lively tabby boy who doesn't read drafts, but sits on them.
Meet Lemon →The trips
South America, Japan, Bali, Taiwan — travel is how I remember that my data is made of people.
Where I've been →Quiet hours
Creative writing, cooking, baking, and arranging flowers — the same care I bring to research.
Take a look →Music
A running playlist for writing, analysis, and long flights.
Have a listen →Lemon.
My most loyal — if unproductive — research assistant.
Lemon joined me in April 2021 — a lively tabby boy, born June 8, 2020. He has firm opinions about which drafts deserve to be sat on (all of them), and an uncanny sense for the exact moment a deadline is approaching.
He doesn't read my papers, but he keeps me company through every revision and reminds me to take breaks. On June 8, the only correct greeting is "Happy Birthday, Meow."
Places that surprised me.
I love road trips and the freedom of exploring the world at my own pace — travel is how I remember that my data is made of people.
The parts that don't fit on a CV.
The same care I bring to a research design, I bring to a Sunday loaf or a bouquet.
Writing
prose & poetryCreative writing is where I think without a regression table — the place ideas go before they become evidence. Selected pieces, coming soon.
Cooking & baking
since 2017Bread, pastries, and the occasional ambitious cake. Nothing brings smiles to a table faster than something still warm from the oven.
On repeat.
A running playlist for writing, analysis, and long flights.
Playlists for writing, analysis, and long flights — find me on Spotify.
Listen on Spotify ↗Get in touch.
Always happy to connect — about research, a possible collaboration, or just to say hello.
For research collaborations, please email directly. I aim to respond within a few days.






























